Stay updated with breaking news from Oriol mitj. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Share this article Share this article BARCELONA, Spain, Jan. 18, 2021 /PRNewswire/ Grifols (MCE: GRF, MCE: GRF.P,NASDAQ: GRFS), a global leader in the development of therapies with plasma-derived proteins with a track record of more than 100 years dedicated to enhancing people s health and well-being, today announced it will begin a clinical trial in Spain to evaluate the safety and efficacy of a new COVID-19 drug based on the Grifols immunoglobulin Gamunex®-C and containing anti-SARS-CoV-2 polyclonal antibodies from plasma donors who have recovered from the disease. The new drug would provide immediate post-exposure protection against the virus and would be especially useful as a complement to the vaccine in the early phase after vaccination. In addition, it could protect the elderly and healthcare workers as well as immunocompromised patients for whom vaccination isn t recommended. It could also help contain outbreaks in places where the vaccination hasn t begun ....
Grifols to launch trial for potential COVID-19 therapy The subcutaneously administered immunoglobulin, if successful, would provide rapid immunity against the virus behind the deadly global pandemic. Biopharmaceutical firm Grifols, which specializes in development of therapies harnessing plasma-derived proteins, has announced it is kicking off a clinical trial in Spain to test the viability of a potential COVID-19 treatment. Based on the company’s immunoglobulin Gamunex-C and containing polyclonal antibodies, the drug at the center of the study reportedly has the potential to deliver immunity against the virus. According to researchers, the novel drug could provide immediate post-exposure protection against the COVID-19 virus, with the potential to complement vaccines in the early post-vaccination phase. The company predicts it could be useful in safeguarding the elderly, healthcare workers, immunocompromised patients and other vulnerable ....
The concert experiment ara.cat - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ara.cat Daily Mail and Mail on Sunday newspapers.